Lipid Lowering Therapy for a Patient with Diabetes
Ms. Jones is a 62-year-old Hispanic female who has a past medical history of diabetes and hypertension. Her LDL-C was 174 mg/dL prior to initiating statin therapy. Her 10-year ASCVD risk was >7.5% using the pooled cohort equations. She is on appropriate guideline-directed medical therapy for hypertension, and her blood pressure is at goal.
Ms. Jones returned to clinic today. She states adherence with optimal lifestyle modifications and atorvastatin 20 mg PO daily. Her fasting LDL-C is now 108 mg/dL (decreased 38% from baseline). Her non-HDL-C is 173 mg/dL, and her triglycerides are 324 mg/dL. She is willing to take additional therapy to lower her ASCVD risk.
According to the 2016 ACC Expert Consensus Decision Pathway (ECDP) on non-statin therapies, which of the following recommendations should be considered for this patient?